|
| 34954454 | Generation of three iPSC lines from dilated cardiomyopathy patients carrying a pathogenic LMNA variant. | Stem Cell Research | 2022 |
| 35385754 | Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons. | Cell Reports | 2022 |
| 35679369 | Cellular and Engineered Organoids for Cardiovascular Models. | Circulation Research | 2022 |
| 32671814 | Generation of Quiescent Cardiac Fibroblasts Derived from Human Induced Pluripotent Stem Cells. | Methods in Molecular Biology | 2022 |
| 35244869 | Deconvoluting the Cells of the Human Heart with iPSC Technology: Cell Types, Protocols, and Uses. | Current Cardiology Reports | 2022 |
| 34411974 | Generation of three induced pluripotent stem cell lines (SCVIi014-A, SCVIi015-A, and SCVIi016-A) from patients with LQT1 caused by heterozygous mutations in the KCNQ1 gene. | Stem Cell Research | 2021 |
| 32365198 | Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies. | Cardiovascular Research | 2021 |
| 34019817 | Human induced pluripotent stem cell-derived atrial cardiomyocytes carrying an SCN5A mutation identify nitric oxide signaling as a mediator of atrial fibrillation. | Stem Cell Reports | 2021 |
| 33847746 | A call to action for new global approaches to cardiovascular disease drug solutions. | Eur Heart J | 2021 |
| 34279605 | Endocardial/endothelial angiocrines regulate cardiomyocyte development and maturation and induce features of ventricular non-compaction. | Eur Heart J | 2021 |
| 33895197 | Reconstructing the heart using iPSCs: Engineering strategies and applications. | Journal of Molecular and Cellular Cardiology | 2021 |
| 33790786 | Human Induced Pluripotent Stem Cells as a Screening Platform for Drug-Induced Vascular Toxicity. | Frontiers in Pharmacology | 2021 |
| 33681306 | Race and Genetics in Congenital Heart Disease: Application of iPSCs, Omics, and Machine Learning Technologies. | Front Cardiovasc Med | 2021 |
| 34051449 | Generation of three heterozygous KCNH2 mutation-carrying human induced pluripotent stem cell lines for modeling LQT2 syndrome. | Stem Cell Research | 2021 |
| 33876947 | A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. | Circulation | 2021 |
| 34302664 | CRISPRi/a Screening with Human iPSCs. | Methods Mol Biol | 2021 |
| 33338435 | Effects of Cryopreservation on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Assessing Drug Safety Response Profiles. | Stem Cell Reports | 2021 |
| 34746854 | Protocol to measure contraction, calcium, and action potential in human-induced pluripotent stem cell-derived cardiomyocytes. | STAR Protocols | 2021 |
| 34719260 | Impact of the COVID-19 Pandemic on Cardiovascular Science: Anticipating Problems and Potential Solutions: A Presidential Advisory From the American Heart Association. | Circulation | 2021 |
| 34948064 | Modeling Transposition of the Great Arteries with Patient-Specific Induced Pluripotent Stem Cells. | International Journal of Molecular Sciences | 2021 |
| 31504255 | Improving the engraftment and integration of cell transplantation for cardiac regeneration. | Cardiovascular Research | 2020 |
| 32169105 | Gut microbiota and cardiovascular disease: opportunities and challenges. | Microbiome | 2020 |
| 32164890 | Stem Cell-Derived Cardiomyocytes and Beta-Adrenergic Receptor Blockade in Duchenne Muscular Dystrophy Cardiomyopathy. | J Am Coll Cardiol | 2020 |
| 32584494 | High-throughput Preparation of DNA, RNA, and Protein from Cryopreserved Human iPSCs for Multi-omics Analysis. | Current Protocols in Stem Cell Biology | 2020 |
| 33073248 | Primer on Biomarker Discovery in Cardio-Oncology: Application of Omics Technologies. | JACC: CardioOncology | 2020 |
| 31242035 | Generation of Endothelial Cells From Human Pluripotent Stem Cells. | Arteriosclerosis, Thrombosis, and Vascular Biology | 2019 |
| 30605412 | Convergences of Life Sciences and Engineering in Understanding and Treating Heart Failure. | Circ Res | 2019 |
| 30768178 | Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell. | Cardiovascular Research | 2019 |
| 31490059 | Nanoscale Technologies for Prevention and Treatment of Heart Failure: Challenges and Opportunities. | Chem Rev | 2019 |
| 31278749 | A computational model of induced pluripotent stem-cell derived cardiomyocytes incorporating experimental variability from multiple data sources. | Journal of Physiology | 2019 |
| 31077805 | The West coast regional safety pharmacology society meeting update: Filling translational gaps in safety assessment. | | 2019 |
| 31219556 | Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients. | European Heart Journal | 2019 |
| 31328865 | Clinical Trial in a Dish: Personalized Stem Cell-Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT-Prolonging Drugs. | Clinical and Translational Science | 2019 |
| 30944437 | Complex heritability in cardiomyopathy. | Nature Biomedical Engineering | 2019 |
| 31011193 | Harnessing cell pluripotency for cardiovascular regenerative medicine. | Nature Biomedical Engineering | 2018 |
| 28735360 | Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. | Cardiovasc Drugs Ther | 2017 |